OPKO Health (LTS:0KCS) Financial Strength: 5 (As of Jun. 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0KCS OPKO Health Inc LTS:0KCS
57 GF Score
Price $1.34
GF Value $1.08
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is OPKO Health Financial Strength?

OPKO Health LTS:0KCS -3.60% 57 Financial Strength is 5 as of Jun. 2026, which is at its 10-year median of 5.00. GuruFocus rates LTS:0KCS with a GF Score™ of 57/100 and a GF Value™ of $1.08 (Modestly Overvalued). The stock has 6 warning signs investors should review.

OPKO Health has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

OPKO Health did not have earnings to cover the interest expense. OPKO Health's debt to revenue ratio for the quarter that ended in Jun. 2026 was 0.61. As of today, OPKO Health's Altman Z-Score is -0.35.


OPKO Health  (LTS:0KCS) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

OPKO Health has the Financial Strength Rank of 5.


OPKO Health Financial Strength Related Terms


LTS:0KCS vs CSTL, FRNM, PSNL: Financial Strength Comparison

For the Diagnostics & Research subindustry, OPKO Health's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OPKO Health Financial Strength vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's Financial Strength distribution charts can be found below:

* The bar in red indicates where OPKO Health's Financial Strength falls into.


LTS:0KCS
57GF Score
OPKO Health Inc LTS:0KCS
Financial Strength is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OPKO Health Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

OPKO Health's Interest Expense for the months ended in Jun. 2026 was $-11.4 Mil. Its Operating Income for the months ended in Jun. 2026 was $-25.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $375.1 Mil.

OPKO Health's Interest Coverage for the quarter that ended in Jun. 2026 is

OPKO Health did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

OPKO Health's Debt to Revenue Ratio for the quarter that ended in Jun. 2026 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2026 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(22.955 + 375.128) / 654.32
=0.61

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

OPKO Health has a Z-score of -0.35, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -0.35 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Financial Strength →
What does a Financial Strength of 5 mean?
OPKO Health (LTS:0KCS) has a Financial Strength of 5 as of Jun. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on OPKO Health and its competitors. This is near median its historical median of 5.00. Over the past decade, OPKO Health's Financial Strength has ranged from 4.00 to 8.00.
Is OPKO Health's Financial Strength too high?
OPKO Health's current Financial Strength of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. Overall, OPKO Health has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OPKO Health's Financial Strength compare to CSTL and FRNM?
OPKO Health's Financial Strength of 5 can be compared against companies in the Medical Diagnostics & Research industry. Historically, OPKO Health's own Financial Strength has ranged from 4.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Medical Diagnostics & Research company?
A good Financial Strength depends on the Medical Diagnostics & Research industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on OPKO Health and its competitors. OPKO Health's current Financial Strength is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OPKO Health stock overvalued right now?
Based on GuruFocus' analysis, OPKO Health (LTS:0KCS) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.08, compared to a current price of $1.34 — trading 24.1% above its estimated fair value. The current Financial Strength is 5, which is near median its 10-year median of 5.00. OPKO Health's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For OPKO Health (LTS:0KCS), the current Financial Strength is 5 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OPKO Health (LTS:0KCS) Overvalued in 2026?

Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued. The current stock price of $1.34 is trading 24.1% above its estimated GF Value™ of $1.08. GuruFocus considers OPKO Health to be Modestly Overvalued.

Key valuation signals for LTS:0KCS:

  • Financial Strength: 5 (near median its 10-year median of 5.00)
  • GF Value™: $1.08 vs. price of $1.34 (24.1% above fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the LTS:0KCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OPKO Health Business Description

Address 4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
57GF Score

Get the complete analysis for LTS:0KCS

Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.34
Price
$1.08
GF Value